ArcBest Corp. (ARCB): 2Q26 Adj EPS Beat; Forward Margin Trajectory Slightly Better Than Forecast; Buy

Research evidence excerpt

ArcBest Corp. (ARCB): 2Q26 Adj EPS Beat; Forward Margin Trajectory Slightly Better Than Forecast; Buy

registration number Kinsho 69,

and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and

Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption

tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers

Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell

on an Investment List is determined by a stock’s total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an

Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is

deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region’s Investment Lists

and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across

their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or

other designated committee in each respective region and do not represent a change in the analysts’ investment rating for such stocks.